Search
Search Results
##search.searchResults.foundPlural##
-
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1288PDF: 1089HTML: 220 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1720PDF: 1273HTML: 397 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2090PDF: 860HTML: 262 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2227PDF: 1639HTML: 323 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2515HTML: 292PDF: 920 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2601PDF: 1186HTML: 151 -
IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma
127PDF: 328HTML: 43 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2214PDF: 1740HTML: 387 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3157PDF: 930HTML: 2090 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2521PDF: 803HTML: 1743 -
SOLITARY PLASMACYTOMA
3988PDF: 2228HTML: 1253fIGURES 1,2: 235 -
-
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2386PDF: 1677HTML: 305 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7744PDF: 2456HTML: 1745Table 1.: 228Table 2.: 240Table 3.: 222Table 4.: 216 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1431HTML: 488PDF: 850 -
EFFECT OF FRESH VERSUS CRYOPRESERVED GRAFTS ON FEBRILE NEUTROPENIA AND INFECTIONS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FACTORS DETERMINING MORTALITY. Fresh vs Frozen Grafts: Infection and Outcome
949PDF: 672HTML: 166 -
ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
4140PDF: 1272HTML: 1968Table 1: 209 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1659PDF: 809HTML: 223 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3430PDF: 1503HTML: 4018 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1612PDF: 1065HTML: 263 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2648PDF: 885HTML: 2129 -
-
-
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1679PDF: 609HTML: 239 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3864PDF: 1700HTML: 11661Figures Haase: 221 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3446PDF: 1314HTML: 2234Fi.1 Gritti.Rambaldi: 218 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1343PDF: 478HTML: 18617Figure 1: 174Figure 2: 154Figure 3: 171Figure 4: 210Figure 5: 182 -
DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA
1583PDF: 800HTML: 1493Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 186 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2637PDF: 890HTML: 17578Fig1 Caligaris: 192Fig.2 Caliga: 236
1 - 48 of 48 items







